These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25659276)

  • 21. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
    Sui Z; Chen Q; Fang F; Zheng M; Chen Z
    Vaccine; 2010 Nov; 28(48):7690-8. PubMed ID: 20870054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus.
    Lu X; Liu F; Zeng H; Sheu T; Achenbach JE; Veguilla V; Gubareva LV; Garten R; Smith C; Yang H; Stevens J; Xu X; Katz JM; Tumpey TM
    Virology; 2014 Apr; 454-455():169-75. PubMed ID: 24725943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity.
    Kim MC; Lee YN; Hwang HS; Lee YT; Ko EJ; Jung YJ; Cho MK; Kim YJ; Lee JS; Ha SH; Kang SM
    Vaccine; 2014 Oct; 32(44):5824-31. PubMed ID: 25171841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine.
    Rockman S; Brown LE; Barr IG; Gilbertson B; Lowther S; Kachurin A; Kachurina O; Klippel J; Bodle J; Pearse M; Middleton D
    J Virol; 2013 Mar; 87(6):3053-61. PubMed ID: 23283953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine.
    Ichinohe T; Tamura S; Kawaguchi A; Ninomiya A; Imai M; Itamura S; Odagiri T; Tashiro M; Takahashi H; Sawa H; Mitchell WM; Strayer DR; Carter WA; Chiba J; Kurata T; Sata T; Hasegawa H
    J Infect Dis; 2007 Nov; 196(9):1313-20. PubMed ID: 17922395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines.
    Thueng-in K; Maneewatch S; Srimanote P; Songserm T; Tapchaisri P; Sookrung N; Tongtawe P; Channarong S; Chaicumpa W
    Vaccine; 2010 Sep; 28(41):6765-77. PubMed ID: 20688037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice.
    Bodewes R; Kreijtz JH; Hillaire ML; Geelhoed-Mieras MM; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
    J Gen Virol; 2010 Jul; 91(Pt 7):1743-53. PubMed ID: 20335492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Revisiting the 1976 "swine flu" vaccine clinical trials: cross-reactive hemagglutinin and neuraminidase antibodies and their role in protection against the 2009 H1N1 pandemic virus in mice.
    Xie H; Li X; Gao J; Lin Z; Jing X; Plant E; Zoueva O; Eichelberger MC; Ye Z
    Clin Infect Dis; 2011 Dec; 53(12):1179-87. PubMed ID: 21976461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice.
    Takahashi Y; Hasegawa H; Hara Y; Ato M; Ninomiya A; Takagi H; Odagiri T; Sata T; Tashiro M; Kobayashi K
    J Infect Dis; 2009 Jun; 199(11):1629-37. PubMed ID: 19385735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of protection against H5N1 influenza virus in mouse offspring provided by maternal vaccination with HA DNA and inactivated vaccine.
    Zhang F; Fang F; Chang H; Peng B; Wu J; Chen J; Wang H; Chen Z
    Arch Virol; 2013 Jun; 158(6):1253-65. PubMed ID: 23385327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.
    Sandbulte MR; Jimenez GS; Boon AC; Smith LR; Treanor JJ; Webby RJ
    PLoS Med; 2007 Feb; 4(2):e59. PubMed ID: 17298168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.
    Ninomiya A; Imai M; Tashiro M; Odagiri T
    Vaccine; 2007 May; 25(18):3554-60. PubMed ID: 17293015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibodies Directed toward Neuraminidase N1 Control Disease in a Mouse Model of Influenza.
    Job ER; Schotsaert M; Ibañez LI; Smet A; Ysenbaert T; Roose K; Dai M; de Haan CAM; Kleanthous H; Vogel TU; Saelens X
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29167342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice.
    Prabakaran M; Madhan S; Prabhu N; Geng GY; New R; Kwang J
    Antiviral Res; 2010 May; 86(2):180-7. PubMed ID: 20153776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potent adjuvant effects of novel NKT stimulatory glycolipids on hemagglutinin based DNA vaccine for H5N1 influenza virus.
    Hung JT; Tsai YC; Lin WD; Jan JT; Lin KH; Huang JR; Cheng JY; Chen MW; Wong CH; Yu AL
    Antiviral Res; 2014 Jul; 107():110-8. PubMed ID: 24786174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective immunity elicited by a pseudotyped baculovirus-mediated bivalent H5N1 influenza vaccine.
    Wu Q; Xiao S; Fan H; Li Y; Xu J; Li Z; Lu W; Su X; Zou W; Jin M; Chen H; Fang L
    Antiviral Res; 2011 Dec; 92(3):493-6. PubMed ID: 22020305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
    Luo M; Tao P; Li J; Zhou S; Guo D; Pan Z
    J Virol Methods; 2008 Dec; 154(1-2):121-7. PubMed ID: 18789973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protective efficacy in mice of monovalent and trivalent live attenuated influenza vaccines in the background of cold-adapted A/X-31 and B/Lee/40 donor strains.
    Jang YH; Lee EY; Byun YH; Jung EJ; Lee YJ; Lee YH; Lee KH; Lee J; Seong BL
    Vaccine; 2014 Jan; 32(5):535-43. PubMed ID: 24342248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.